The WPSS-Score is a WHO-classification-based prognostic scoring system for myelodysplastic syndrome, which can be applied – in comparison to the IPSS – at any time during the disease course . While the IPSS was created for use in patients diagnosed with MDS based upon the FAB classification, the WPSS was designed for patients diagnosed with MDS based upon the WHO classification. It was also designed to incorporate information on red cell transfusion need, a characteristic shown to be an independent prognostic factor for patients with MDS. The score was initially developed using data from 426 patients with de novo MDS between 1992 and 2004 and validated in a second cohort of 739 patients diagnosed with de novo MDS from a another institution between 1982 and 2003.
|WHO type||RA/RARS/5q-||RCMD/RCMD-RS||RAEB I||RAEB II|
|Karyotype risk||Low (normal karyotype, del(5q), del(20q), -Y)||Intermediate (all other aberrations)||High (complex karyotype = ≥ 3 anomalies, chromosome 7 anomaly)|
|Very low risk||0 points|
|Low risk||1 points|
|Intermediate risk||2 points|
|High risk||3–4 points|
|Very high risk||5–6 points|